NCT05919069View on ClinicalTrials.gov

A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 16, 2023

Primary Completion Date

September 16, 2024

Study Completion Date

September 16, 2024

Conditions
Hepatic Impairment
Interventions
DRUG

AZD2693

Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment

Trial Locations (3)

32808

Research Site, Orlando

33014

Research Site, Miami Lakes

92377

Research Site, Rialto

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY